🔬 Our R&D team (represented by Adolfo Lopez Noriega, Charlotte Peloso and Fang Liu) will attend the Controlled Release Society 2024 conference (from July 8 to 12 in Bologna, Italy) to provide an overview of some of our R&D programs related to our cutting-edge Long-Acting Injectable technologies through several presentations and posters, including: - Oncology field: Presentation of in vivo data showing the improved immunomodulatory potential of a tumor-targeting monoclonal antibody in melanoma using BEPO® technology for peritumoral administration. - Introduction to BEPO® STAR: Overview of the novel Medincell’s proprietary Long-Acting Injectable technology designed to enhance controlled delivery across a broader range of drugs and therapeutic areas. - Medincell proprietary in vitro release tool: Presentation of an innovative in vitro lab tool designed to accelerate formulation activities and preclinical candidates selection. #Medincell #CRS2024 #LongActingInjectables #Oncology #Innovation #Pharmaceuticals
Medincell’s Post
More Relevant Posts
-
Triple Negative Breast Cancer (TNBC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Merck, Roche, Tesaro, Clovis, Gilead #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech
-
“The Pharma Letter” published an article on accelerating Pierre Fabre's oncology initiatives, following an interview with Théodore Leondaridis Pierre Fabre's global franchise head for innovative Oncology during #ASCO24. 🚀 The journalist highlighted: • Our Focused R&D: Emphasis on oncology, with a significant portion of R&D spending dedicated to this field. 🔬 • Our Precision Medicine Leadership: Commitment to leading in precision medicine, by developing novel agents targeting genetic alterations for melanoma and NSCLC patients with unmet medical needs 🎯 • Regulatory Submissions: A targeted therapy combination for mutated NSCLC submitted to European Authorities and submission of a cell therapy for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV PTLD) to the U.S. FDA in collaboration with Atara Biotherapeutics. 💊 • Our Strategic Partnerships: Partnerships with Pfizer for BRAF/MEK inhibitors, Puma for HER2 inhibitor and Scorpion Therapeutics for EGFR inhibitors. 🤝 • Our Global Expansion: Expansion into China and the US, aiming for 50% of revenue to come from international markets. 🌏 Discover more about our strategic focus in ThePharmaLetter website: https://lnkd.in/eTkYectt Pierre Fabre Group #Oncology #R&D #PrecisionMedicine #NSCLC #GlobalExpansion #PharmaceuticalInnovation #StrategicPartnerships"
-
-
Delighted to have the attended the first official General Assembly meeting of the PSCC Connect network, part of the Paris Saclay Cancer Cluster, this afternoon. I enjoyed hearing the PSCC team explain the working structure, budget and future plans of the network, meeting fellow members and hearing elevator pitches from 20 Oncology start-ups, encompassing ADCs (MIO / McSAF), Biologics (ABCELY), Small-Molecule Drugs (Promontory Therapeutics), Cell Therapies (PERSEA), Anti-Cancer Vaccines (Brenus Pharma, ErVimmune), Drug Repurposing (PEGASCY) and various other domains (HEPHAISTOS-Pharma and so many others...). Photo: various attendees. Inset: Gregory Qushair (Alésia Consulting) with Wahid Awad, Ph.D. MBA (Rosetta Omics). ABCELYARDAN PHARMA Serendip innovations Apmonia Therapeutics Exosome Analytics GIMLI Jalon Therapeutics MSInsight PepKon #oncology #biotechnology #pharmaceuticals #diagnostics #cancer #paris #drugdiscovery #celltherapy #immunotherapy #omics
-
-
Nanobiotix granted Janssen Inc. exclusive, worldwide rights (excluding China and Asian territories) to co-develop and commercialize NANOBIOTIX's NBTXR3, a radio enhancer for the treatment of solid tumors. Nanobiotix will retain the NANORAY-312 study control with manufacturing and supply of NBTXR3 while Janssen will be responsible for Phase II trials in stage 3 lung cancer patients. Nanobiotix will receive $30M up front and $30M in equity in two tranches of $5M and $25M from JJDC with an additional $30M in R&D funding. Nanobiotix is eligible for up to $2.67B in development, regulatory, and commercial milestones including $1.8B for NBTXR3, up to $650M for five indications developed by Janssen, and up to $220M for any new indication developed by Nanobiotix, plus double-digit tiered royalties. See this and similar full deal profiles when you become DealForma customer. #pharma #biopharma #biopharmadatabase
-
-
Timely reminder to learn and demonstrate how you can say NOTHING substantial or of substance in the article, yet "seem" to say something very interesting! DISCLAIMER alert: I do not know this person, and do not pass judgements on the person but only assess the post and the link based on what LinkedIn throws up in my feed.
Any good scientist will tell you that failure is a necessary part of progress. When we attempt to address the most important and difficult questions, we will often fail - but we will learn. I recently authored an article in Evidence-Based Oncology to share how we equip our scientists at @ServierPharmaceuticals with the space and tools to fail better and faster when it comes to tackling difficult and hard-to-treat cancers. Our goal is that they can leverage that information to advance faster toward success. Read my full article here: https://lnkd.in/eCSFdy_3
Why Failing Faster Is the Key to Accelerating Drug Discovery
ajmc.com
-
Our discovery and technology are revolutionizing the treatment of lung cancer. Our latest lung cancer treatment is a groundbreaking medical innovation that effectively manages lung cancer. We gather vast amounts of medical information, data, and clinical experiences, which we process using cutting-edge technology. Our team of scientists at Spudgene analyzes this information using an advanced artificial intelligence-based system. Furthermore, we've incorporated an innovative HOCL nanoparticle drug delivery system that has resulted in an astonishing 92.7% success rate in treating lung cancer at all stages. www.spudgene.com https://lnkd.in/edJG66Gq #Cancer #LungCancer #Biopharmaceutical #Biotech #Healthcare #Medicaladvancement #pharmaceuticals #Cancerresearch #Lungcancertreatment #ArtificialIntelligence
-
🎉 Exciting Milestone Alert at Biond Biologics! 🚀 We are delighted to announce that the first patient has been dosed with BND-35 in a Phase 1 clinical trial, marking the entry of the second program in our innovative pipeline into clinical trials. BND-35 is a distinctive anti-ILT3 blocker designed to enhance the activity of tumor-targeting antibodies. This pioneering therapy offers a novel treatment avenue, particularly beneficial where existing therapies are limited. Initially tested as a monotherapy, BND-35 will subsequently be examined in combination with other drugs, broadening its potential impact. We are enthusiastic about the potential of BND-35 Immuno-Therapy, and will continue to update on the trial progression. 🔗 Read more about the trial #BiondBiologics #CancerResearch #ClinicalTrials #Oncology #Innovation
We'll see you there!